Asthma in pregnancy – Immunological changes and clinical management  by Tamási, Lilla et al.
Respiratory Medicine (2011) 105, 159e164ava i lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / rmedREVIEW
Asthma in pregnancy e Immunological changes
and clinical managementLilla Tama´si a,*, Ildiko´ Horva´th a, Aniko´ Boha´cs a, Veronika Mu¨ller a,
Gyo¨rgy Losonczy a, Michael Schatz baDepartment of Pulmonology, Semmelweis University, 1125 Budapest, Dio´s a´rok 1/C, Hungary
bDepartment of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Boulevard, San Diego,
CA 92111, USA
Received 27 July 2010; accepted 12 November 2010
Available online 8 December 2010KEYWORDS
Asthma;
Clinical implications;
Immunology;
Management;
Pregnancy* Corresponding author. Tel.: þ36 1
E-mail addresses: tamasi@pulm.so
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.11.006Summary
Asthma is one of the most common diseases complicating pregnancy and a risk factor for several
maternal and fetal complications, posing a special challenge for physicians treating asthmatic
pregnant women. Asthma influences the outcome of pregnancy and e vice versa e pregnancy
affects asthma severity with bidirectional immunological interactions that are currently being
examined. Supporting pregnancy-induced immunotolerance is the observation that attenuation
of allergic responses can be detected in controlled asthmatic pregnant patients. However,
uncontrolled asthmatic pregnant women show significant asthma-associated immune reactions,
such as diminished pregnancy specific regulatory T cell proliferation, that may e besides other
factors e influence fetal growth. Uncontrolled, symptomatic asthma may increase the risk of
adverse perinatal outcomes; thus adequate regular anti-asthmatic treatment resulting in
optimal asthma control represents a vital need during pregnancy. This review summarizes immu-
nological changes characterizing pregnancy in asthmatic women togetherwith the clinical impli-
cations of asthma management during pregnancy.
ª 2010 Elsevier Ltd. All rights reserved.ContentsIntroduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Immunological and clinical influence of asthma on pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Effect of pregnancy on the course of asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
Management of asthma during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162355 9733; fax: þ36 1 214 2498.
te.hu, tamasi@sterling-consulting.org (L. Tama´si).
0 Elsevier Ltd. All rights reserved.
160 L. Tama´si et al.Diagnosis and monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Conflict of interest statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163Introduction
Asthma is one of the most common chronic diseases
complicating pregnancy, affecting 3.7e8.4% of all pregnan-
cies.1 Pregnant women with asthma represent a special
challenge for asthma specialists. Asthma influences the
outcome of pregnancy and vice versa e pregnancy affects
asthma severity, and the underlying immunological mecha-
nisms of this interaction are currently being studied. Asthma
represents a risk factor for several maternal and fetal
complications, such as asthma exacerbations, use of oral
corticosteroids, hospitalizations due to asthma attacks,
preeclampsia, gestational hypertension, preterm delivery,
cesarean delivery, low birth weight, intrauterine growth
restriction, and fetal death.2e7 Thus, managing asthma
during pregnancy requires careful decision making, optimal
physician training, and frequent patient consultations with
physicians treating these patients. Adequate management
of asthma andmaintenance of optimal asthma control during
pregnancy decrease maternal and neonatal risks.8,9
Immunological and clinical influence of asthma
on pregnancy
Pregnancy is characterized by a physiological immunosup-
pression, an immunological tolerance that protects the
fetus from maternal immune response against paternal
antigens expressed by the fetus.10 Physiological pregnancy
has been described as a Th2-dominated state, and current
studies show that a trimester dependent, pregnancy-induced
increase in regulatory T cell (Tregs) number has a key role in
the maintenance of maternal tolerance to paternal antigens
during pregnancy, exerting an inhibition on the activation of
effector T lymphocytes and NK cells.11 Diminished numbers
of Tregs in pregnancy were associated with immunological
rejection of the fetus as well as preeclampsia and low fetal
birth weight.12 Of note, Tregs exert inhibitory effects on
natural killer lymphocytes responsible for protection against
viruses13that may contribute to increased susceptibility to
viral infections (e.g. influenza) during pregnancy, as
observed by H1N1 influenza in 2009.14
Asthma is traditionally also considered as allergic T helper
cell 2 (Th2) type inflammation that leads to bronchial
hyperresponsiveness, airway obstruction and e in some
cases e tissue remodeling.15 Immunological changes in
asthmatic women during pregnancy are not well elucidated.
Previously we found signs of pregnancy-induced attenuation
of allergic responses in asthmatic pregnant women. Acti-
vated pools within CD4 and CD8 T cells were larger, and the
number of natural killer T (NKT) cells was increased both in
non-pregnant asthmatic and in healthy pregnant subjects
(compared with non-pregnant healthy controls), but in(mostly well controlled) pregnant asthmatics no further
lymphocyte activation was observed, suggesting that the
immunosuppressive effect of uncomplicated pregnancy may
blunt lymphocyte activation which characterizes asthma.16
In addition, as a sign of an enhanced T cell apoptosis,
higher number of CD95þ T cells was detected in healthy
pregnant than in healthy non-pregnant women, together
with a positive correlation between CD95þ T cell counts and
birth weights in healthy but not in asthmatic pregnancies.16
On the other hand, in another study enrolling mostly not
well-controlled asthmatic pregnant women, a substantial
number of peripheral interferon(IFN)-g producing cells was
detected, and a significant negative correlationwas revealed
between the number of IFN-g positive Tcells and birthweight
of newborns, suggesting that fetal growth restriction (intra-
uterine growth restriction e IUGR) can be related to active,
asthma-associated maternal immune reactions.17 In addi-
tion, considering another inflammatory marker, heat shock
protein(Hsp)-70, higher circulating levels were detected in
asthmatic than in healthy pregnant women, and fetal birth
weight was lower in pregnancies complicated with asthma,
again suggestinge a relationship between asthmatic immune
responses and altered fetal growth.18 In a recent study we
found lower prevalence of peripheral Treg cells in asthmatic
compared to healthy pregnant women.19 In healthy preg-
nancies the supposed relationship between strengthened
maternal immunotolerance and the physiological growth of
the fetus was reflected by a positive correlation between
Treg prevalence and the birth weight of newborns. On the
contrary, no correlation was detected between Treg preva-
lence and neonatal birth weight in the pregnancies of asth-
matic women, either examining all pregnancies in asthmatic
women or stratifying the analyses by female or male
offspring. In addition, in asthmatic pregnant patients treated
regularly with inhaled corticosteroids (ICS) a trend towards
higher Treg cell prevalence was observed compared to those
with inadequate adherence to ICS treatment.19
Immunological changes characterizing pregnancy in
asthmatic women may contribute to the increased risk for
maternal and fetal complications. In a database cohort of
13 100 pregnant asthmatics, a 35% increased risk of perinatal
mortality was observed in the pregnancies of women with
asthma.4 Another recent study8of pregnant women with
physician-diagnosed asthma evaluated their asthma control
repeatedly during pregnancy based on symptom frequency
and interference with daily activities and sleep and reported
hospitalizations and unscheduled clinic visits for asthma
exacerbations. According to their results, the incidence of
preterm delivery is higher among patients with inadequate
asthma symptom control during the first part of pregnancy
compared with patients with adequate asthma control, and
patients who are hospitalized for asthma during pregnancy
have a higher incidence of preterm delivery compared with
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there may be a risk for preterm delivery posed by poorly
controlled maternal asthma.8 According to a population-
based cohort of 13 007 pregnancies in asthmatic women,
mothers with severe andmoderate asthma during pregnancyFigure 1 Immunological changes characterizing asthmatic preg
growth. Absence of trimester dependent regulatory T cell elevat
lymphocyte and NK cell activation and proliferation. Elevated numb
immune mediated alteration of fetal growth and enhancement of
Foxp3 e fork head/winged-helix transcription factor box p3; L e l
associated antigen; APC e antigen presenting cell; MHC e major
antigen; Treg e regulatory T cell; NK e natural killer;/ stimulatihave a higher risk of small for gestational age babies than
those with mild asthma.20 Finally, asthma also affects
newborns’ morphometry, as asthma severity was associated
with an increased head circumference: birth weight ratio in
a recent multicenter prospective observational cohortnancy (red arrows) that may compromise physiological fetal
ion in asthmatic pregnancy leads to impaired inhibition of T
ers of activated effector T lymphocytes and NK cells may cause
allergic/asthmatic responses. (CD e cluster of differentiation;
igand; TCR e T cell receptor; CTLA e cytotoxic T lymphocyte-
histocompatibility complex antigen HLA e human leukocyte
on; --j e inhibition).
162 L. Tama´si et al.study.21 Some immunological mechanisms characterizing
asthmatic pregnancy and presumably leading to altered
fetal growth are presented in Figure 1.
Effect of pregnancy on the course of asthma
Pregnancy may alter the natural course of asthma. Asthma
improves during pregnancy in about one-third, remains the
same in another one-third, and worsens in one-third of
pregnant women. More severe asthma before pregnancy
increases the risk of worsening during pregnancy, and there
is a concordance between the courses of asthma during
subsequent pregnancies.22 Asthma-specific quality of life in
early pregnancy is related to subsequent asthma morbidity
during pregnancy.23
Severity of asthma symptoms during pregnancy may also
be influenced by fetal gender. Worsened asthma symptom-
s24and higher incidence of IUGR25 were observed in asthmatic
pregnant women with female fetuses. Our latest results also
demonstrated a higher risk for lack of asthma control and
altered fetal growth in the pregnancies of asthmatic women
carrying female fetuses.19 Obesity is associated with an
increased risk of asthma exacerbations during pregnancy as
well.3 Pregnancy-induced immunological tolerance may be
altered in obese pregnant asthmatic women, as a lower
prevalence of naive T cells was observed in obese compared
to non-obese asthmatic pregnant patients.19 In addition,
maternal obesity is associated with higher risk of non-
pulmonary complications (e.g. preeclampsia, gestational
diabetes, and gestational hypertension) in asthmatic preg-
nant patients.3 However, in spite of the above information,
the immunological mechanisms causing alterations in the
course of asthma, or serving as biomarkers for disease dete-
rioration during pregnancy are mostly unknown.
Management of asthma during pregnancy
Diagnosis and monitoring
The diagnosis of asthma is usually known already before
pregnancy. However, if first symptoms occur duringTable 1 Main patient educational topics for asthmatic pregnan
Main patient educational topics
1. Information about the disease
2. Use of inhaler devices
3. Adherence to treatment and importance of
regular visits
4. Environmental control measures to reduce
exposure to allergens and irritants
5. Self-treatment action plangestation, reduced forced expiratory volume in one second
(FEV1) or ratio of FEV1 to forced vital capacity (FVC) and a 12%
or greater improvement in FEV1 after inhalation of rapid
acting beta-agonist confirm the diagnosis of asthma. Testing
bronchial hyperresponiveness is contraindicated during
pregnancy (because of the lack of safety data); thus women
with a clinical picture of new-onset asthma without spiro-
metric confirmation of the diagnosis should be treated for
asthma during pregnancy. Skin prick tests are not recom-
mended during pregnancy (risk of systemic reactions), but
blood tests for specific IgE antibodies to suspected allergens
may be evaluated.26
Due to the bidirectional interactions between asthma
and pregnancy and alterations of asthma severity during
pregnancy, establishing optimal asthma management during
gestation often represents a special challenge for the
attending physician. Aim of the treatment is to achieve and
maintain control of the disease. Fractioned concentration of
nitric oxide present in exhaled breath (FENO) has been eval-
uated as a non-invasive tool for assessing airway inflammation
in asthma,27 and our recent study provided data supporting
it’s applicability in asthmatic pregnant patients as well.28
Pregnancy-induced hyperpnea causes somewhat higher
arterial oxygen (pO2 100e105 mmHg) and lower arterial
carbon-dioxide (PCO2 32e34 mmHg) partial pressures
during normal pregnancy.29,30 Thus, even mild maternal
hypoxaemia may represent respiratory compromise during
pregnancy. Generally, maintenance of an arterial oxygen
saturation of at least 95% measured by pulse oximetry is
recommended to ensure sufficient oxygenation in both the
mother and the fetus.26
Treatment
Asthmatic pregnant patients should be educated regarding
their disease and its treatment (Table 1), as recommended in
current guidelines.7,26 Active (but not passive) smoking is
associated with increased asthma symptoms and fetal
growth abnormalities among pregnantwomenwith asthma.31
Smoking cessation is necessary for asthmatic pregnant
women, not only because of adverse effects of smoking on
asthma and on pregnancy but also due to the known highert patients.
Description
Basic information about asthma and it’s
relationship to pregnancy.
Facts regarding maternal and fetal outcomes.
Demonstration of correct use of devices
prescribed to the patient.
Necessity of regular visits and appropriate
controller medication during pregnancy
complicated with asthma.
Avoidance of known allergens and smoking.
Written schedule for maintenance therapy and
doses of rescue medication for increased symptoms.
Education about signs of asthma exacerbation and
seeking urgent or emergency care.
Education about controller medication increase or
oral corticosteroid use for increased symptoms.
Table 2 Steps of asthma maintenance therapy during pregnancy (LTRA e leukotriene-receptor antagonist; LABA e long-acting
beta-agonist).
Step Preferred controller
medication
Alternative controller medication
1 None e
2 Low-dose inhaled
corticosteroid
LTRA, cromolyn, theophylline
3 Medium-dose inhaled
corticosteroid
Low-dose inhaled corticosteroid þ
LABA or LTRA or theophylline
4 Medium-dose inhaled
corticosteroid þ LABA
Medium-dose inhaled corticosteroid þ
LTRA or theophylline
5 High-dose inhaled
corticosteroid þ LABA
e
6 High-dose inhaled corticosteroid þ
LABA þ oral corticosteroid
e
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smoke.32
Most of the data on adverse effects of asthma medica-
tions in pregnancy are reassuring.26 Observational studies of
using inhaled beta-agonists and inhaled corticosteroids
during pregnancy showed no increase in perinatal risks.33e36
The use of bronchodilators during pregnancy was associated
with an increased risk of gastroschisis among infants in one
study,37 and higher risk of cardiac defects was observed in
newborns of asthmaticmothers in another study.38 However,
asthma exacerbation itself during pregnancy may increase
the risk of congenital malformations.39
According to currently available safety data, albuterol is
the reliever medication of choice during pregnancy. Bude-
sonide is the preferred inhaled corticosteroid according to
available data in human pregnancies.35 Long-acting inhaled
beta-agonists formoterol and salmeterolmay be used as add-
on therapy in pregnant patients if symptoms occur despite
regularly used inhaled corticosteroid therapy. Leukotriene-
receptor antagonists montelukast and zafirlukast seem also
to be safe during gestation, but the available human data are
limited.9 In one recent study enrolling 180 asthmatic preg-
nant women taking montelukast, no increase in the rate of
major congenital malformations was observed.40
Treatment of asthma during pregnancy must be aimed
at controlling the disease (symptoms and lung function
abnormalitiesaswell). Asthmaticwomenwithwell-controlled
asthma should continue taking their medications during
pregnancy. Although guidelines recommend consideration of
a step down in therapy in non-pregnant patients with well-
controlled asthma for at least 3 months,7,9 controller treat-
ment may be maintained in pregnant patients in order to
reduce the risk of loss of asthma control during pregnancy.
Therapy should be increased by one step in patients with
asthma that is not well controlled (Table 2). A two-step
increase, a course of oral corticosteroids, or both should be
recommended for women with asthma that is very poorly
controlled (Table 2).26
Monthly asthma control assessment is recommended for
women who require controller therapy during pregnancy.
Optimal obstetrical care of not well-controlled asthmatic
pregnant patients means more frequent ultrasonographic
examinations (to monitor fetal growth, which can be
affected by uncontrolled asthma) and assessment of fetalwell-being (nonstress testing from the 32nd gestational
week). During labor and delivery the use of asthma medi-
cations should be continued. Women who are currently
taking systemic corticosteroids or who have received
several short courses of systemic corticosteroids during
pregnancy are recommended to receive intravenous corti-
costeroids during labor and for 24 h after delivery.26
In conclusion, asthma is one of the most common chronic
diseases complicating pregnancy and influencing its outcome.
Generally, although uncontrolled asthma may increase the
risk of adverse perinatal outcomes, women with adequately-
treated and well-controlled, disease during pregnancy do not
appear to have a substantial increased risk of maternal or
fetal complications. Frequent communication between
obstetricians, asthma specialists, and general practitioners is
vital in the treatment of asthma during pregnancy, as well as
the development of an effective partnership between the
patient and her health care professionals.
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